59thANNUAL CONFERENCE OF THE PARTICLE THERAPY CO-OPERATIVE GROUP
Online Meeting 4-7 June 2021

Panel Discussions

FLASH

Saturday 5 June 2021, 12:00pm UTC / GMT

Dr. Lei Dong
Physics Perspective

Dr. Dong is a professor and the director of medical physics division at Hospital of the University of Pennsylvania. A nationally recognized expert in radiation therapy, Dr. Dong co-authored more than 250 peer-reviewed articles and 15 book chapters. He conducted innovative research and clinical development in image guided radiation therapy and proton therapy. He is a fellow of the American Association of Physicists in Medicine (AAPM). He served as a member of AAPM Science Council, the Physics Track Chair at the annual scientific meeting of American Society for Radiation Oncology (ASTRO). He is also a member of the education council for the Particle Therapy Co-Operative Group (PTCOG).

Dr. John Breneman
Clinician's Perspective

Dr. John Breneman is the medical director of the Cincinnati Children’s/UC Health Proton Therapy Center. His research interests focus on the use of radiotherapy for childhood cancer, and the implementation of new technology for radiotherapy. He is a member of the FlashForward Consortium which was formed to study the biologic mechanisms, technical solutions, and clinical applications of FLASH radiotherapy. He is the principal investigator of the FAST-01 first-in-human trial using FLASH radiotherapy for the treatment of metastatic bone tumors.

Prof. Marie-Catherine Vozenin
Biology Perspective

The research projects that I develop with my team aim at finding innovative tools able to protect normal tissue and enhance tumor control. In this context, we have developed a novel modality of radiation therapy called FLASH-Radiotherapy that minimizes normal tissue toxicity and eradicates tumors in various organs including the brain, lung and skin and in various species including mice, zebrafish, pigs and cats. Much of our recent work has focused on investigating the entirely different biological response induced after FLASH exposure. Importantly, we have worked to secure the translation of FLASH-RT into clinical trials for human patients with cancer.

Dr. Emanuele Scifoni
Modelling Perspective

Emanuele Scifoni is “Primo Ricercatore” (Senior Research Scientist) at TIFPA, the Trento Institute for Fundamental Physics and Applications, a recently established research center of the National Institute for Nuclear Physics (INFN) in Trento (Italy). He was born in Rome and got his PhD in theoretical chemical physics in Genoa. After an initial career mostly based on theoretical /computational methods for quantum chemistry and molecular physics, moving to FIAS (Frankfurt Institute for Advanced Studies, Goethe University) from 2007 he focused his research interests in radiation biophysical modelling of ion beams for particle therapy.
He moved to the Biophysics department at GSI (Helmholtz Center for Heavy Ions research) in Darmstadt in 2010, where he started the long-lasting collaboration with Michael Krämer and Marco Durante and where he contributed substantially to the new developments in the research treatment planning code for particles TRiP98, including new ions, multiple ions optimization and the kill painting method for hypoxic tumors, as well as to to the track structure code TRAX, including its chemical stage extension TRAX-CHEM. He finally moved to Trento in 2016 where he was appointed as Primo Ricercatore at TIFPA-INFN and Contract Professor at the University of Trento, and where he also contributed to the setup of the Trento Proton Beam Experimental Facility and to the establishment of the BiMeR (BioMedical Radiation Physics) research group.
He’s presently Principal Investigator and coordinator for the large INFN project Call “MoVe IT”- Modeling and verification for Ion Beam Treatment Planning, and had a leading role in several successful international grants and projects in the field of particle therapy.
His most recent research interests focus mainly on biological treatment planning for protons and ion beams, and on elucidating mechanistic features of oxygenation interplay with radiation at the radiation chemistry level, including novel insights in FLASH radiotherapy.

Clinical Research & Patient Selection Ethics

Monday 7 June 2021, 10:15am UTC / GMT

Dr. Siddarth Laskar
Tata Memorial Centre

Dr Siddhartha Laskar currently works as Dy Director Academics, Tata Memorial centre (TMC) & Professor of Radiation Oncology, TMC, Mumbai, India. His areas of specialisation includes management of Childhood Malignancies, Haematological Malignancies, & Bone & Soft Tissue Malignancies. His special interests includes high precision radiation therapy, brachytherapy & total body irradiation (TBI) for bone marrow transplantation (BMT). He is also involved in indigenisation & development of newer technologies.
Dr Laskar has more than 150 scientific publications in peer reviewed journals & is the principal investigator for many ongoing research projects. His research interests have been focussed at optimising the role radiation therapy in the management of childhood cancers, lymphomas & leukemias, & bone/soft tissue malignancies. He has contributed towards formulation of institutional & national treatment guidelines published by the Tata Memorial Hospital & Indian Council of Medical Research (ICMR) and has pioneered & developed innovative techniques for interstitial brachytherapy especially in children. He is actively involved in national & international educational activities. Dr Laskar has served as member secretary of the TMC institutional ethics committee & has been part of the ICMR task force for development of guidelines for clinical research. He serves as an expert faculty for international bodies like the International Atomic Energy Agency (IAEA) and professional groups like the International Society of Paediatric Radiation Oncology (PROS), International Lymphoma Radiation Oncology Group (ILROG), International Society of Paediatric Oncology (SIOP), & European Society for Therapeutic Radiotherapy/Oncology (ESTRO). Dr Laskar leads the National Hadron Beam Therapy Facility at TMC, Mumbai.

Dr. Lane Rosen
Willis-Knighton Medical Center, Lousiana
Lane R. Rosen MD FACRO is a board-certified radiation oncologist and Medical Director of Radiation Oncology at Willis-Knighton Health System. He has been at the helm since 1997 and has overseen the department's transformation to an international leader in advanced cancer care technology. Dr. Rosen attended LSU School of Medicine in Shreveport with a residency in Radiation Oncology at George Washington University in Washington, D.C. where he served as Chief Resident. With the support of his excellent team at Willis-Knighton in Shreveport, Louisiana, the department has pioneered several radiotherapy technologies. Dr Rosen was the first physician to deliver TomoTherapy SBRT as well as Image-Guided Intensity Modulated Proton therapy on a commercial compact proton unit. Dr Rosen practices full-time at Willis-Knighton but is an Assistant Professor of Internal Medicine, Gynecology and Radiology at LSU Medical School in Shreveport and an Adjunct Instructor of Radiation Oncology at Tulane Medical Center in New Orleans. He and his group have welcomed international visitors interested in Proton Therapy, TomoTherapy, and Brachytherapy.

Dr. Michael Penniment
Royal Adelaide Hospital

Prof Michael Penniment AM. MBBS, FRANZCR,MBA, Director of Radiation Oncology Royal Adelaide Hospital and Visiting Radiation Oncologist
Alan Walker Cancer Care Centre Prof Michael Penniment is a Senior Radiation Oncologist with interests in the application of new technologies in radiotherapy and the provision of services to rural and remote areas. He established the Alan Walker Cancer Care Centre (AWCCC) in Darwin and is Director of Radiation Oncology at the Royal Adelaide Hospital. He is the clinical lead for the Australian Bragg Centre, the first proton therapy unit in the southern hemisphere. This has federal and state government financial support and will begin operations in 2024.
He completed an MBA (Adelaide University 2007) and is nationally and internationally recognised as an expert in cancer infrastructure and business planning.
He chairs a number of national and international research projects, in particular in the areas of business planning for new radiation facilities, improving indigenous cancer care, and quality of life in cancer treatment. He was honoured in the 2021 Australia Day National Honours as a Member of the Order of Australia

Nancy Mendenhall MD
University of Florida Proton Therapy Institute

Nancy Mendenhall MD, FASTRO, Associate Chair and Medical Director of the UF Health Proton Therapy Institute, has more than 30 years of experience in Radiation Oncology and specializes in the areas of breast cancer, Hodgkin disease, lymphomas and pediatric cancers, as well as prostate cancer. Her primary focus for the past 14 years has been the expansion of the use of proton therapy.
Prior to assuming her current role as the Medical Director for the University of Florida Health Proton Therapy Institute (UFHPTI) in 2006, she was Department Chair for Radiation Oncology at the University of Florida College of Medicine, and the first female Chair in the College’s history. Dr. Mendenhall is an enthusiastic teacher who is invited to lecture at numerous national and international meetings, delivering more than 100 educational lectures in her career, and has become a sought-after visiting professor, panelist and refresher course lecturer. She is also an endless source of inspiration for young scientists in the field of radiation and has trained more than 87 residents and fostered over 75 resident peer-reviewed publications.
As the Editor-in-Chief of the International Journal of Particle Therapy, she, along with Dr. Bill Mendenhall as Operations Editor, helped to found the first peer-reviewed international academic journal for particle therapy. Dr. Mendenhall and her team received a five-year, $11.9 million award in 2017 from the Patient-Centered Outcomes Research Institute which supports the research study ‘A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr ( COMPPARE)’ which is a large-scale, pragmatic clinical study to compare outcomes between proton and conventional radiation in 3,000 men with prostate cancer for which she is lead Principle Investigator. Also, she recently received the 2020 Paulus Award for Clinical Excellence from the University of Florida for ‘Making a difference for patient care; an unfailing moral compass; engagement at every level of patient care; and championing teamwork.’. She also won the University of Florida’s College of Medicine Clinical Science Researcher of the Year in 2018 and was included in the Wall of Fame for Distinguished UF College of Medicine Alumni in 2014.

Innovative Computational Technologies

Sunday 6 June 2021, 12:45pm UTC / GMT

Prof. Antoni Rucinski
GPU-Monte Carlo treatment planning: the Fred platform

Antoni Rucinski is a medical physics researcher currently working at CCB Krakow proton beam therapy centre at the Institute of Nuclear Physics (IFJ) PAN in Krakow (Poland). His topics of interest range from clinical medical physics, to nuclear physics and radiobiological modeling for radiotherapy applications. He dedicated his research career to the development of computational and experimental methods to reduce physical and biological range uncertainties in clinical proton therapy. Being on the boundary of physics, medicine and biology, he believes that integrated or averaged quantities like dose, LETd and RBE are not the proper quantities to describe the biological effect of charged particles in tissues. Instead, to accurately model radiation effects it is necessary to include the nanoscale effect of DNA damage in particle therapy dosimetry, and eventually apply this approach in charged particle therapy treatment planning.
Antoni Rucinski graduated from University of Heidelberg in 2013 where he worked on the development of treatment planning strategies for moving targets and especially for prostate cancer patients. During his time in Heidelberg and Heilbronn (Germany), he has been trained as a medical physics expert working in the clinical routine of photon and particle therapy. Between 2015 and 2017 he has been a postdoctoral fellow in Rome at the National Institute of Nuclear Physics (INFN) working on charged secondary radiation produced by ion beams for range monitoring. From 2017 he is based in Krakow and leads research projects with the goals to improve radiobiological modeling and range monitoring in proton beam therapy.

Christian Graeff
4D-treatment planning and beam delivery

Christian Graeff received his PhD in Biomedical Engineering at the Hamburg University of Technology in 2010. Since 2012, he is group leader of Medical Physics in the Biophysics department of GSI, Darmstadt, Germany, and since 2018, he is the deputy scientific director of this department.
His main research interest are advanced treatment planning and delivery strategies for particle therapy, in particular for moving targets. In 2014, Dr Graeff conducted the first carbon ion cardiac ablation study in a large animal model in collaboration with the Mayo Clinics and University Clinc Heidelberg. Dr Graeff devised 4D-optimization strategies for conformal motion mitigation, which his group implemented in GSI’s 4D-treatment planning system TRiP4D. In a collaboration with the Italian hadrontherapy center CNAO, these strategies were added to the research version of the clinical dose delivery system of CNAO and have been experimentally validated both at GSI and CNAO.
Dr. Graeff has published 42 peer reviewed manuscripts and more than 100 conference contributions. He received the 2nd Behnken-Berger award in 2014 and the Günther-von-Pannewitz-Award of the German Radiooncological Society in 2018.

Dr. Dan Nguyen
AI in treatment planning

Dr. Dan Nguyen is a scientist with expertise in radiation therapy treatment planning, deep learning, and optimization techniques and algorithms. He completed his Ph.D. in Biomedical Physics in 2017 at the University of California Los Angeles (UCLA), where he worked extensively on 4π Radiotherapy, Fluence Map Optimization, and Direct Aperture Optimization techniques under the guidance and mentorship of Dr. Ke Sheng.
Dr. Nguyen was recruited to the Division of Medical Physics and Engineering, Department of Radiation Oncology at UT Southwestern in 2017 as a faculty member. He was a founding member of the multiple-investigator lab called the Medical Artificial Intelligence and Automation (MAIA) Laboratory, which was focused to innovate, develop, and apply artificial intelligence technologies to empower clinicians—especially those with less experience or limited resources—for improved patient care. He works very closely with Dr. Steve Jiang in researching and applying deep learning technologies to various facets of radiotherapy, including treatment planning, medical imaging, and outcome prediction.



Conference Secretariat: C-IN, 5. kvetna 65, 140 21 Prague 4, CZE | tel.: +420 261 174 301 | fax: +420 261 174 307
Home | Sitemap | Copyrights and Trademarks | Privacy Policy | info@ptcog59.org | Copyright © 2019 ptcog59.org
Powered and created by E-WORKS - web studio | XHTML 1.0 | CSS 2



Conference Secretariat: C-IN, 5. kvetna 65, 140 21 Prague 4, CZE | tel.: +420 261 174 301 | fax: +420 261 174 307
Home | Sitemap | Copyrights and Trademarks | Privacy Policy | info@ptcog59.org | Copyright © 2019 ptcog59.org
Powered and created by E-WORKS - web studio | XHTML 1.0 | CSS 2

Access
Conference
Portal